Cost-Effectiveness Analysis of Amlodipine–Candesartan and Amlodipine–Furosemide in Hypertensive Inpatients at RSUD Dr. Loekmono Hadi Kudus, 2023

https://doi.org/10.22146/jmpf.103302

Yulia Pratiwi(1*), Mutia Arum Masitoh(2), Annis Rahmawaty(3), Mersi Riyanti(4)

(1) Institut Teknologi Kesehatan Cendekia Utama Kudus, Central Java
(2) Institut Teknologi Kesehatan Cendekia Utama Kudus, Central Java
(3) Institut Teknologi Kesehatan Cendekia Utama Kudus, Central Java
(4) RSUD Dr Loekmonohadi Kudus, Central Java
(*) Corresponding Author

Abstract


Background: Hypertension is a major public health problem and a leading risk factor for cardiovascular morbidity and mortality. In hospitalized patients, combination antihypertensive therapy is frequently used to achieve optimal blood pressure control, which may lead to increased healthcare costs. Therefore, evaluating the cost-effectiveness of commonly used antihypertensive combinations is essential to support rational drug selection in hospital settings.

Objectives: This study aims to analyze the cost-effectiveness of amlodipine–candesartan and amlodipine–furosemide combination therapies for inpatient hypertension treatment at RSUD dr. Loekmono Hadi Kudus in 2023.

Methods: This non-experimental, descriptive study employed a retrospective design using medical record and cost data from 88 hypertensive inpatients. Patient characteristics, length of hospital stay, therapeutic effectiveness, and direct medical costs were analyzed. Therapeutic effectiveness was defined as the proportion of patients achieving target blood pressure based on JNC VIII guidelines. Cost-effectiveness was assessed using the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER).

Results: The amlodipine–candesartan combination demonstrated a lower ACER (Rp48,229 per 1% effectiveness) than amlodipine–furosemide (Rp90,275). The ICER value (−Rp597,651) indicated that amlodipine–candesartan was both more effective and less costly. Higher costs in the amlodipine–furosemide group were associated with injectable drug use and a greater proportion of prolonged hospital stays.

Conclusion: Amlodipine–candesartan was more cost-effective than amlodipine–furosemide for managing hypertensive inpatients. These findings support the preferential use of amlodipine–candesartan when clinically appropriate to optimize both clinical outcomes and healthcare resource utilization.


Keywords


ACER; Antihypertensive Combination; Cost Effectiveness; Hypertension; Hypertensive Patients; ICER

Full Text:

PDF


References

  1. Page MR. The JNC 8 hypertension guidelines: an in-depth guide. Am J Manag Care. 2014;20(1 Spec No.):E8.
  2. Organization WH. Hypertension. World Health Organization. Preprint posted online 2025.
  3. Kesehatan BKP. Prevalence, Impact, and Efforts in Controlling Hypertension and Diabetes in Indonesia. Badan Kebijakan Pembangunan Kesehatan. Preprint posted online 2024.
  4. Jannah LM. The Relationship of Lifestyle with Hypertension in Bumiayu Kabupaten Bojonegoro. Jurnal Berkala Epidemiologi. 2018;6(2):157-165. doi:10.20473/JBE.V6I22018.157-165
  5. Muhadi M. JNC 8: Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa. Cermin Dunia Kedokteran. 2016;43(1):54-59. doi:10.55175/cdk.v43i1.11
  6. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi:10.1001/JAMA.2013.284427
  7. Putri LSA, Satriyasa BK. Gambaran pola penggunaan obat antihipertensi pada pasien hipertensi di instalasi rawat inap RSUP Sanglah Denpasar tahun 2016. Jurnal Medika Udayana. 2019;8(6):1-8.
  8. Sumiati L. Analisis Efektivitas Biaya Terapi Antihipertensi Pada Pasien Hipertensi Rawat Inap di RSU Pancaran Kasih Gmim Manado. Pharmacon. 2018;7(1).
  9. Andayani TM. Farmakoekonomi Prinsip Dan Metodologi. UGM; 2013.
  10. Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372(5):447-455. doi:10.1056/NEJMSA1406751
  11. Rahayu A, Afdhal AF, Hasan D, Suwarna F, Meila O. Analisis Efektivitas Biaya Terapi Antihipertensi Kombinasi Tetap Di Satu Rumah Sakit Jakarta Selatan. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 2020;10(1):1. doi:10.22146/jmpf.43667
  12. Baroroh F, Sari A, Masruroh N. Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients. Open Access Maced J Med Sci. 2019;7(22):3837-3840. doi:10.3889/oamjms.2019.515
  13. Hasanah NU, Dewi NMAR, Saputra YD. Cost-effectiveness analysis of amlodipine and candesartan in the inpatient setting at Mataram University Hospital in Indonesia, 2021. Pharmacy Education. 2024;24(3):228-233. doi:10.46542/pe.2024.243.228233
  14. Nur Rahmi Hidayati, Rinto Susilo, Tomi, Sulistiorini Indriaty, Dewi Kartika. Analisis Efektivitas Biaya Kombinasi Candesartan-Amlodipin dengan Candesartan-Furosemide Pasien Hipertensi Rawat Inap RS XXX. Medical Sains : Jurnal Ilmiah Kefarmasian. 2022;7(4):951-962. doi:10.37874/ms.v7i4.585
  15. Yulistina F, Deliana SM, Rustiana ER. Korelasi Asupan Makanan, Stres, dan Aktivitas Fisik dengan Hipertensi pada Usia Menopause. Unnes Journal of Public Health. 2017;6(1):35. doi:10.15294/ujph.v6i1.13695
  16. Lestari A, Hediya R, Yunitasari E. Hipertensi pada wanita menopause; Sebuah tinjauan literatur. Wellness And Healthy Magazine. 2020;2:309-313. doi:10.30604/well.022.82000121
  17. Astuti E, Suwardianto H, Yuliantin N. 5 Th Octave Music Therapy Menurunkan Tekanan Darah Terhadap Penderita Hipertensi. Ejournal Stikes Baptis. 2016;1.
  18. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases. 2019;74(1):120-131. doi:10.1053/j.ajkd.2018.12.044
  19. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/J.KINT.2023.10.018
  20. Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25(8):1630-1646. doi:10.1681/ASN.2013060601
  21. Mehata S, Shrestha N, Mehta R, et al. Prevalence, awareness, treatment and control of hypertension in Nepal: data from nationally representative population-based cross-sectional study. J Hypertens. 2018;36(8):1680-1688. doi:10.1097/HJH.0000000000001745
  22. Bambungan YM, Oetari R, Satibi S. Analisis Biaya Pengobatan Hipertensi Pada Pasien Rawat Inap di RSUD Sorong. 2-TRIK: TUNAS-TUNAS RISET KESEHATAN. 2017;7(2):72-76. Accessed December 27, 2024. https://2trik.jurnalelektronik.com/index.php/2trik/article/view/7203
  23. Sukmadriyani Y. Analisis Efektivitas Biaya Pengobatan Hipertensi Dengan Diltiazem Dan Amlodipin Pada Pasien Rawat Inap Di RSUD Kabupaten Sukoarjo Tahun 2016. Universitas Setia Budi Surakarta; 2017.
  24. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4634/2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa. Kementerian Kesehatan Republik Indonesia. Preprint posted online May 2021. https://kemkes.go.id/app_asset/file_content_download/1700108499655598d3c61e16.60954826.pdf
  25. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). Pedoman Tatalaksana Hipertensi pada Penyakit Kardiovaskular: Edisi Pertama. Preprint posted online 2015. https://www.inaheart.org/wp-content/uploads/2025/10/Pedoman-Tatalaksana-Hipertensi-Pada-Penyakit-Kardiovaskular.pdf
  26. Bulsara KG, Patel P, Cassagnol M. Amlodipine. StatPearls; 2025.
  27. Gopal S, Patel P, Makaryus AN. Candesartan. StatPearls; 2025.
  28. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008;10(1 Suppl 1):27-32. doi:10.1111/j.1524-6175.2007.08029.x
  29. Kollias A, Foukarakis E, Karakousis K, HYPEDIA Study Group, Stergiou GS. Implementation of the 2018 ESC/ESH Guidelines for the management of hypertension in primary care: the HYPEDIA study. J Hum Hypertens. 2023;37(6):449-454. doi:10.1038/s41371-022-00713-w
  30. Arumugham VB, Shahin MH. Therapeutic Uses of Diuretic Agents. StatPearls; 2025.
  31. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
  32. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00512.x
  33. Khan TM, Patel R, Siddiqui AH. Furosemide. StatPearls; 2025.
  34. Fitria N, Zazna Syaputri Y, Mardatillah M, Akram M, Nasif H. Amlodipine-Candesartan Combination: A Cost-Effective Strategy for Successful Therapy of Hypertension. Jurnal Sains Farmasi & Klinis. 2024;11(1):32-38. doi:10.25077/jsfk.11.1.32-38.2024
  35. Amal S, Karlina L, Astuti D, Hidayah H. Analisis Efektivitas Biaya (Cost Effectiveness Analysis) Penggunaan Kombinasi Dua Obat Antihipertensi pada Pasien Hipertensi Rawat Jalan di RSUD Karawang. Pharma Xplore Jurnal Ilmiah Farmasi. 2021;6(2):13-26. doi:10.36805/farmasi.v6i2.1938
  36. Baroroh F, Sari A. Cost Effectiveness Analysis Therapy Combination of Candesartan-Amlodipine and Candesartan-Diltiazem on Hypertensive Outpatients. PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia). 2018;14(2):188. doi:10.30595/pharmacy.v14i2.1952
  37. Kementerian Kesehatan Republik Indonesia Badan Kebijakan Pembangunan Kesehatan. Pedoman Umum Penilaian Teknologi Kesehatan Di Indonesia. (Suryawati S, others, eds.). Lembaga Penerbit BKPK; 2022. https://repository.badankebijakan.kemkes.go.id/id/eprint/5670/1/PEDOMAN%20UMUM%20PENILAIAN%20TEKNOLOGI%20KESEHATAN%20DI%20INDONESIA.pdf



DOI: https://doi.org/10.22146/jmpf.103302

Article Metrics

Abstract views : 2 | views : 2

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats